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Abstract: Risk assessment tools, i.e., validated risk prediction algorithms, to estimate the patient’s
10-year risk of developing cardiovascular disease (CVD) should be used to identify high-risk people
for primary prevention. Current evidence confirms that appropriate monitoring and control of risk
factors either reduces the likelihood of CVD or slows down its progression. It is thus crucial that
all health professionals make appropriate use of all the available intervention strategies to control
risk factors: from dietary improvement and adequate physical activity to the use of functional
foods, food supplements, and drugs. The gut microbiota, which encompasses 1 × 1014 resident
microorganisms, has been recently recognized as a contributing factor in the development of human
disease. This review examines the effect of both some vegetable food components belong to the
“protein food group” and the underexploited protein-rich hempseed on cholesterolemia and gut
microbiota composition.
Keywords: protein food group; cholesterol; microbiota; soybeans; lupins; peas; hempseed; functional
food; LDL-receptor; PCSK9
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide, mostly
due to ischaemic heart disease and stroke (both haemorrhagic and ischaemic). International and
national policies now support targeting of interventions to reduce risk of CVD among high-risk
patients. Accordingly, there is an increasing number of risk scores available to aid in the identification
of individuals with a high CVD risk [1,2].
Almost these entire scores estimate personalized prognosis in terms of both absolute risk and life
expectancy free of CVD. The use of these lifetime estimations has been endorsed by prevention
guidelines to facilitate doctor–patient communication or cultivate patient motivation and, as a
consequence, patient compliance [3–5].
Consequently, appropriate monitoring and control of risk factors, carried out in a timely and
continuous manner, can in fact now play an even greater role in prevention. Several randomized
clinical trials and meta-analyses have shown that such management either reduces the likelihood of
CVD or slows down its progression (Figure 1) [6–8]. Moreover, hypercholesterolemia play a key role in
determining CVD and the lowering of plasma low-density lipoprotein (LDL) cholesterol (LDL-C) levels
is associated with CVD risk reduction, as documented by data obtained in clinical practice [8–10].
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Figure 1. Treatment effect linked to cholesterol levels on the potential age of clinical cardiovascular 
event appearance. Treated means a multifactor intervention, i.e., dietary and lifestyle modifications 
plus the consumption of functional foods plus the use of drugs. 
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The Western lifestyle, including over-feeding of highly refined diets and sedentary behaviour, is 
associated with high prevalence of chronic conditions, such as CVD, inflammatory bowel disease 
(IBD) and type II diabetes, which carry a remarkable socioeconomic burden [17–20]. Proposed 
mechanisms range from generation of bioactive metabolites to inducing systemic low-grade 
inflammation. 
The gut microbiota, which includes the trillions of resident microorganisms, including bacteria, 
viruses, fungi, and protozoa, has been recently recognized as a contributing factor in the 
development of human disease [20,21]. These organisms are involved in digestion, protection 
against invading organisms, and regulation of metabolism and immunity. An alteration of these 
microbial functions has been associated with acute and chronic disease, and development of 
autoimmune disorders. Diet also notably has an immediate and dramatic impact on microbial 
structure, and may be the single most important driver of gut bacterial composition and function 
(Figure 2) [22,23]. The effects of high protein consumption on gut microbiota composition are not yet 
extensively studied, but are of increasing importance [21]. 
We review the effects of vegetable proteins on hypercholesterolemia and on the gut microbiota. 
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Figure 1. Treatment effect linked to cholesterol levels on the potential age of clinical cardiovascular
event appearance. Treated means a multifactor intervention, i.e., dietary and lifestyle modifications
plus the consumption of functional foods plus the use of drugs.
It is thus mandatory that all health professionals make appropriate use of all the available
intervention strategies to control risk factors: from dietary improvement and adequate physical
activ ty (i.e , lifestyle changes) to the use of functional fo ds, fo d sup lements, and drugs [8,1 –16].
The Western lifestyle, including over-feeding of highly refined iets and sedentary behaviour, is
associated with hig prevalenc of chronic conditions, such as CVD, inflammatory bowel disease (IBD)
and type II diabetes, which carry a remarkable socioeconomic burde [17–20]. Proposed mechanisms
range from generation of bioactive metab lites to inducing systemic l w-grade inflammation.
The gut microbiota, which includes the trillions of resident microorganisms, including bacteria,
viruses, fungi, and prot zoa, as been recently recog ized as a contributing f ctor in the development
of human disease [20,21]. These organisms a involved in digestion, protection against invading
organisms, and regulation of m tabolism and immunity. An alteration of th se microbial functions has
been as ociate with acute and chronic disease, and devel pment of autoimmune disorders. Diet also
notably h s an immediate and dr matic impact on microbial structure, and may be th single most
important driver of gut bacterial composi ion and function (Figure 2) [22,23]. The effects of high protein
cons mption on gut microbiota co position are not yet extensively studied, but are of i creasing
importance 1].
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Figure 2. Impact of the dietary intake on gut microbiota and on human disease. Athero CVD
(cardiovascular disease) means Atherosclerotic cardiovascular disease.
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We review the effects of vegetable proteins on hypercholesterolemia and on the gut microbiota.
2. Plasma Cholesterol Control: From Soy to Hempseed
Recent meta-analyses have elucidated the role of diet interventions in the reduction of plasma
low-density lipoprotein (LDL) cholesterol (LDL-C) levels. Many studies have found that the most
commonly prescribed dietary interventions (a reduction of dietary cholesterol, and an increase in
polyunsaturated fatty acids) have both a limited impact on LDL-C concentrations (about −3%) [24,25],
and a low compliance to these dietary manipulations over time [8]. Moreover, the reduction of dietary
saturated fats does not appear to reduce either CVD risk or all-cause mortality, even in the presence of
a marked reduction of plasma LDL-C levels [26].
On the other side of the coin, other dietary protective effects that are not mediated by LDL-C
variations may play a major role in CVD prevention [3]. This review will examine the effect of: (a) some
old cholesterol-lowering food components belong to the “protein food group” as reported by the
Dietary Guidelines for Americans 2015–2020 (U.S. Department of Health and Human Services); (b) the
underexploited protein-rich hempseed [27].
2.1. Glycine Max
Glycine max, normally named as soybean, is widely cultivated for its lipid content, and indeed is
the top oilseed produced worldwide [28]. In 2013, the United States accounted for about 30% of world
soy production, even though historically soy consumption come from Asian countries [29]. In addition,
soybean is a legume recognized as a valuable source of nutrients, i.e., they contain high-quality protein
(~40%); polyunsaturated fatty acids (~18%); carbohydrates (~8%); and dietary fibres (~17%) [30].
2.1.1. Experimental Evidences
Soybean protein consumption has been shown to successfully reduce cholesterolaemia in a variety
of animal models [30–32]. In vivo and in vitro studies have attempted to establish a link between
the hypocholesterolaemic effects of soybeans and the activation/depression of liver LDL receptor
(LDL-R) [33–35]. Much of the focus on soybean has been directed toward the hypocholesterolemic
properties of bioactive peptides coming from soy protein digestion, which exert their effects primarily
through mechanisms involving the LDL-R, and bile acid regulation [30,36,37].
2.1.2. Clinical Studies
Starting from the earliest studies in the Seventies, a large number of clinical studies have
supported the health benefits of soybeans in humans, where elevated plasma cholesterol levels
were of genetic or non-genetic origin [31,38,39]. For example, prospective observational studies in
the Asian population showed that a significant reduction of total and LDL-C plasma concentrations
was observed when consuming a daily amount of about 6 g of soybean protein [31]. Moreover,
a meta-analysis of 38 controlled clinical trials pointed out that there is a direct correlation between soy
proteins consumption (an average of 47 g/day) and the lowering of the plasma lipid levels [40].
It is important to highlight that the above mentioned cholesterol-reducing effects of soy proteins
became the basis of the soy health claim relating 25 g soy protein with a reduced risk of CVD in the
United States [41] and Canada [42], but not Europe (DOI: European Food Safety Authority). However,
other constituents in soy have been shown to confer many health benefits, including reduction of CVD
risk, and are worthy of further examination.
2.2. Lupinus
Lupins belong to four major species, i.e., Lupinus albus, Lupinus angustifolius, Lupinus luteus, and
Lupinus mutabilis. L. albus and luteus mainly grow in the Mediterranean area, L. angustifolius mainly
in Australia and South America, and L. mutabilis in the Andes. Lupin seeds are also considered
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very useful, from a nutritional point of view, because they contain up to 42% protein, 10% fat, 10%
carbohydrates, and 30% fibre [31,43].
2.2.1. Experimental Evidences
In a study performed by our group, rats were fed for 28 days Nath’s hypercholesterolaemic diets
containing 20% casein or L. angustifolius proteins [44]. After 14 and 28 days of dietary treatment,
L. angustifolius-fed rats markedly lowered plasma LDL-C levels compared to those measured in rats
fed casein diet, (−60.1%, and −61.2%, respectively) [45]. In these animals higher hepatic mRNA
levels of sterol regulatory element-binding protein-2 (SREBP-2), a major transcriptional regulator of
intracellular cholesterol levels, as well as of cholesterol 7 α-hydroxylase (CYP7A1), the rate-limiting
enzyme in bile acid biosynthesis, were observed, thus providing a definite mechanism underlying
the plasma cholesterol concentration reduction [44,45]. In addition, in a rabbit model, lupin protein
administration, compared to casein, also exerted a remarkable reduction of cholesterolemia [46–48].
Studies in lactating rats fed diet containing 20% of L. angustifolius protein markedly reduced both total
cholesterol and triglyceride plasma levels [49]. A reduction of cholesterolemia and triglyceridemia
were also found in apo-E deficient mice fed 10% L. angustifolius protein for 16 weeks [50–53].
2.2.2. Clinical Studies
A randomised, double-blind, clinical study was designed with the aim at evaluating the
effect of plant proteins (lupin proteins or pea proteins) and their combinations with soluble fibres
(oat fibres or apple pectin) on plasma total cholesterol concentrations. Each group consumed two
bars containing specific protein/fibre combinations: the reference group consumed casein cellulose.
Highly significant reductions of cholesterolemia were observed in subjects receiving the bars with
lupin protein + cellulose, or casein + apple pectin, or pea protein + oat fiber or apple pectin [54].
2.3. Pisum Sativum L.
Pea (Pisum sativum L.) is one of the main legumes cultivated and consumed worldwide due to
its high nutritional value, low content of antinutritional substances and proven health-promoting
actions [55]. Pea seeds consist of 21–22% of proteins and contain 1.5% lysine and the usefulness of
pea in human nutrition is determined mainly by this high protein content and exogenous amino
acids [56,57].
2.3.1. Experimental Evidences
Several studies using different animal models demonstrated the impact of pea proteins on
plasma lipids. In these studies, a marked hypolipidemic activity of this dietary component was
observed [58–61]. A major focus of these studies was the investigation of potential mechanisms
explaining the impact of pea proteins on circulating plasma total cholesterol and triglycerides.
Whereas no relevant variations of SREBP-2, hydroxymethyl-glutaryl-CoA (HMG-CoA) reductase
and CYP7A1 were observed, the LDL-R expression was significantly elevated in pea protein-fed
animals compared with controls [59,61–63].
2.3.2. Clinical Studies
Peas, as well as dietary non-oil-seed pulses have received particular attention for their ability
to reduce the risk of cardiovascular disease. Their consumption was associated with a reduction in
cardiovascular disease [64] and with improvements in LDL-C levels in observational trials [65–67].
2.4. Cannabis sativa L.
The great interest for hempseed (Cannabis sativa L.) depends on its nutritional content (whole
seed): 35.5% oil, 24.8% protein, 20–30% carbohydrates, 27.6% total fiber (5.4% digestible and 22.2%
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non-digestible fiber), and 5.6% ash. Moreover, the concentration of the main anti-nutritional factors,
such as phytic acid, condensed tannins, and trypsin inhibitors, is low [68]. The seed of the non-drug
cultivar of industrial hemp is an underexplored protein source. The use of hempseed, as human
food, dates back probably to pre-history, also with fiber utilization as textile. Cultivation of this
plant has been banned for some decades in many developed countries because of the morphological
similarity with marijuana. Cultivation of non-drug cultivars of industrial hempseed has become
legal again in recent years because of the prevalence of low ∆9-tetrahydrocannabinoil (THC) cultivars
(THC content < 200 mg/kg) [68].
2.4.1. Experimental Evidences
Hempseed proteins mainly consist of a storage protein, edestin, accounting for 60–80% of total
protein content, with albumin accounting for the rest. Hydrolysis of hempseed proteins allowed the
identification of a number of peptides mainly belonging to edestin 1, 2, and 3, and also to other protein
families [69]. Zanoni et al. by HPLC ESI-MS/MS analyses identified 90 peptides from 33 proteins.
These hydrolysates showed that the highest number of active peptides was from 6 isoforms of edestin 1,
other peptides belonged to well-known proteins characteristic of plants. Hempseed peptides did not
impair HepG2 cell viability and, at concentrations between 0.1 and 1 mg/mL, showed a powerful
activity on HMG-CoA reductase [69]. Moreover, exposure to hempseed peptides raised LDL-R activity
and LDL uptake at concentrations above 0.5 mg/mL. Uptake was raised by 200% by hempseed peptides
at concentrations of 0.5 mg/mL. Interestingly, hempseed peptides at concentrations of 0.5 mg/mL or
higher also markedly raised proprotein convertase subtilisin/kexin type 9 (PCSK9) protein levels, thus
resembling the activity of statins, i.e., reducing cholesterol synthesis and raising LDL-R and PCSK9
protein levels [70,71]. A more recently study showed the production of a high number of peptides,
in the weight range of 1500–2100 Da [72]. A number of peptides showed additional bioactivities,
particularly edestin 2 also added a significant antagonism to the angiotensin converting enzyme (ACE)
as well as a glucose uptake stimulating activity [72].
2.4.2. Clinical Studies
No clinical data on lipid changes are available up to now.
3. Gut Microbioma Modulation: From Soy to Hempseed
3.1. Glycine Max
Several recent studies have reported that the consumption of soybean or soy foods may alter the
composition and population of the gut microbiota [73,74]. Efforts have also been made to elucidate
the precise components in soybean that may contribute to modulation of the gut microbiota. It has
been hypothesized that soybean protein can serve as nitrogen and energy sources for bacteria, which
support their growth and maintenance in the gut [75,76].
An and colleagues observed a shift of bacteria composition in the Firmicutes phylum, specifically
an increase in the abundance level of Enterococcus and decreased levels of Ruminococcus and
Lactobacilli, after 16 days of supplementation of 20% soybean protein in a Wistar rat model [77].
Butteiger and colleagues supplemented soy protein concentrates in a Western style diet for 3 weeks
and observed significant increases in Bifidobacteriaceae, Clostridiales, and Deferribacteraceae and
decreases in Bacteroidetes in a Golden Syrian hamster model [74].
The major bacteria that can metabolize protein in the gut are Clostridium and Bacteroides [78].
Differential changes of bacteria in Clostridium and Bacteroides genera upon soy protein consumption
may indicate a complex interaction between soy protein and gut bacteria, as well as among the bacteria
in the gut. Significantly higher levels of Bacteroides and Prevotella were observed in individuals
consuming soy milk containing 49.5% β-conglycinin and 6% glycinin compared to those consuming
soy milk with 26.5% β-conglycinin and 38.7% glycinin [73], indicating that a higher β-conglycinin to
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glycinin ratio in protein content may preferentially promote the growth of bacteria in the Bacteroidetes
phylum [28].
3.2. Pisum Sativum L.
As nutritional substrates, proteins are prone to spontaneously undergo non-enzymatic
glycosylation (glycation), which can alter their molecular structure, making them highly bioactive.
Glycated food proteins are able to modify the bacterial intestinal ecosystem, which is of great
importance for the optimal usage of nutrients and maintenance of both intestinal homeostasis and
balanced health status of the consumer. Due to their high lysine content, the pea proteins are susceptible
to spontaneous glycation during storage and cooking [79].
The impact of glycated pea proteins on the intestinal bacteria from a healthy human was
investigated using a protocol aimed to better understand the impact of glycated food products
on homeostasis of the gut ecosystem of healthy persons. The glycated pea proteins affected the
growth of gut commensal bacteria, particularly Lactobacilli and Bifidobacteria, whose levels increased
significantly. There was a corresponding shift in the bacterial metabolites with increased levels of the
short chain fatty acids, i.e., acetate, propionate lactate, and butyrate. Moreover, intestinal bacteria
were able to utilize these pea proteins, indicating that the energy encrypted in these glycated proteins,
partially inaccessible for gastric enzymes, may be recovered by gut microbiota [79]. The results
obtained in this study expand our current knowledge of the interactions between glycated food
proteins and gut microbiota.
In addition, glycated pea proteins were shown to beneficially modulate bacterial adhesion to
enterocytes as well as its profile [80]. Such changes in microbial composition may beneficially impact
the intestinal environment and exert a health-promoting effect in humans. However, further research
on the interaction between glycated proteins and the human digestive system is required to determine
their beneficial nutritional effect.
Unfortunately, no data are yet available showing a direct activity of lupin and hempseed proteins
on gut microbiota.
4. Conclusions
In summary, we attempt to summarize the current knowledge of the effects of vegetable bioactive
components on hypercholesterolemia and gut microbiota. On the basis of the existing literature, it is
manifest that vegetable proteins, beyond the cholesterol-lowering effects, can potentially modulate
gut microbiota. In most cases, the shift in gut microbiota composition, such as increases in probiotics
(Lactobacilli and Bifidobacteria) and the Firmicutes to Bacteroidetes ratio, favours a health-promoting
role of soybean and glycated pea proteins. However, several critical issues need to be addressed for
potential future directions.
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